Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 42INDUSTRY 15NETWORK 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Radiotherapy 34Gemcitabine 24Docetaxel 24bicalutamide 23Goserelin 21Paclitaxel 19Cisplatin 19Doxorubicin 18Carboplatin 18Flutamide 17Leuprolide 16Radiotherapy, Conformal 13Etoposide 13Filgrastim 12Prednisone 11Gene Expression Profiling 11Gonadotropin-Releasing Hormone 10Radiotherapy, Intensity-Modulated 9Vincristine 8Vinblastine 8Triptorelin Pamoate 8Magnetic Resonance Spectroscopy 8Cyclophosphamide 8Buserelin 8Androgen Antagonists 8Surgical Procedures, Operative 7Radiation 7Polymerase Chain Reaction 7Methotrexate 7Estramustine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Pluvicto × Genitourinary × Clear all
NCT06783348 2026-06-04

RENALUT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Recruiting
48 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡